甲状腺乳头状微小癌ATA风险评分的前瞻性验证:ITCO真实世界研究
该研究基于意大利甲状腺癌观测站前瞻性连续纳入的5038例甲状腺乳头状癌患者,其中2345例(46.5%)为微小癌。微小癌患者仅3%被ATA风险分层归为高危、1%诊断时有远处转移,1年随访时5%为生化不完全应答、2.3%为结构不完全应答。诊断时远处转移是微小癌结构不完全应答的最佳预测因子(OR 5.13,95%CI 1.11-23.73,P=.04);在925例全甲状腺切除加放射性碘治疗亚组中,ATA高危是最佳预测因子(OR 5.47,95%CI 1.42-21.04,P=.01)。
要点
- 微小癌患者1年结构不完全应答率仅2.3%,生化不完全应答率5%。
- 诊断时远处转移是微小癌结构不完全应答的最佳预测因子(OR 5.13)。
- 全甲状腺切除加放射性碘治疗亚组中ATA高危预测结构不完全应答(OR 5.47)。
核心结论
- 该研究在大型系列中证实微小癌初始结局良好,并证明ATA风险分类可可靠预测微小癌患者的生化与结构持续性疾病。
- 远处转移虽罕见,仍是1年随访时结构持续性疾病的最佳预测因子。
- 这些发现强调应基于全面风险分层而非仅依据肿瘤大小制定个体化管理策略。
研究设计与样本
- 前瞻性队列研究,连续纳入意大利甲状腺癌观测站(NCT04031339)中组织学诊断为甲状腺乳头状癌、具备完整病理、临床、治疗信息及1年随访结果的患者。
- 共纳入5038例患者,其中2345例(46.5%)为微小癌(肿瘤小于1 cm)。
- 亚组分析纳入925例接受全甲状腺切除加放射性碘治疗的患者。
主要发现
- 微小癌患者肿瘤病理特征更惰性:仅3%按ATA风险分层系统被归为持续或复发疾病高危,1%诊断时即有远处转移。
- 微小癌结局显著更好:仅5%为生化不完全应答,2.3%为结构不完全应答(SIR)。
- 微小癌中诊断时远处转移是SIR的最佳预测因子(OR 5.13,95%CI 1.11-23.73,P=.04)。
- 925例全甲状腺切除加放射性碘治疗亚组中,SIR的最佳预测因子为ATA高危(OR 5.47,95%CI 1.42-21.04,P=.01)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The risk of recurrence of papillary thyroid carcinoma (PTC) smaller than 1 cm (microPTC) is low. Predictors of disease persistence in microPTC are still unclear. OBJECTIVE: To compare the clinical and pathological characteristics of microPTCs with macrocarcinomas (PTC > 1 cm), identifying the predictors of biochemical and structural incomplete response 1 year after initial treatment in microPTC. METHODS: We included patients consecutively enrolled in the Italian Thyroid Cancer Observatory (NCT04031339), and selected patients with a histological diagnosis of PTC for whom complete pathological, clinical, treatment information, and results at the 1-year follow-up visits were available. RESULTS: Among 5038 patients in the cohort, 2345 (46.5%) had a microPTC. Patients with microPTCs had tumors with more indolent pathological features: only 3% of patients were classified as high risk according to the American Thyroid Association (ATA) risk stratification system for persistent or recurrent disease and 1% had distant metastases at diagnosis. MicroPTCs had a significantly better outcome: only 5% had a biochemical response and 2.3% a structural incomplete (SIR) response. Distant metastases at diagnosis were the best predictor of SIR in microPTCs (OR 5.13, 95% CI 1.11-23.73, P = .04). In a subgroup of 925 patients treated by total thyroidectomy and radioiodine treatment, the best predictor of SIR was the ATA high risk (OR 5.47, 95% CI 1.42-21.04, P = .01). CONCLUSION: Our study confirms the favorable initial outcome of microPTC in a large series. We demonstrate that the ATA risk classification is reliable in predicting biochemical and structural persistence in patients with microPTC. Distant metastases, although rare, remain the best predictor of structural persistence at 1-year follow-up. These findings underscore the importance of tailored management strategies based on comprehensive risk stratification, rather than solely on tumor size.
引用
- De Leo S, Brigante G, D'Elia S, et al. Prospective Validation of ATA Risk Score for Papillary Thyroid Microcarcinoma: An ITCO Real-World Study. J Clin Endocrinol Metab. 2025. PMID: 40165363. doi:10.1210/clinem/dgaf190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。